###### Significance of this study

What is already known about this subject?
=========================================

-   Regular physical activity prevents development of diabetes mellitus.

What are the new findings?
==========================

-   Physical activity---measured using a simple pedometer---is an effective measure for objectively measuring physical activity in lifestyle studies and clinical practice.

-   There is a highly, clinically significant dose-response relationship of pedometer steps with development of diabetes in a prediabetic population.

How might these results change the focus of research or clinical practice?
==========================================================================

-   Practitioners caring for those with prediabetes should ask patients to track physical activity with pedometer steps.

-   To prevent the development of diabetes, at-risk patients should obtain up 10 000 steps per day.

Physical activity is related to a plethora of clinical outcomes, including all-cause mortality, cardiovascular disease (CVD), stroke, and diabetes mellitus. These relationships remain even after adjusting for body mass.[@R1] Physical activity is an essential component of a number of lifestyle intervention studies for CVD[@R3] and diabetes,[@R7] but the effects of physical activity alone have rarely been studied prospectively in a clinical trial in subjects at high risk of diabetes or CVD, one exception being the LOOK AHEAD study of patients with diabetes.[@R11] As intensive lifestyle intervention studies are expensive, burdensome, and unlikely to be replicated it may be worthwhile to study relationships of physical activity in long-term clinical outcome trials of individuals with a high burden of risk where secondary observational analyses of these relationships may be more tenable. We have used data from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Study[@R12] for this purpose.

Physical activity was measured objectively using pedometers at baseline in all participants. Data for the association between physical activity and the incidence of CVD have been published previously.[@R13] Here we use the baseline pedometer data to address the hypothesis that objectively measured baseline physical activity, irrespective of study arm assignment, would be related to the development of diabetes.

Research design and methods {#s1}
===========================

NAVIGATOR and study participants {#s1-1}
--------------------------------

NAVIGATOR (ClinicalTrials.gov: NCT00097786) was a double-blind, randomized, placebo-controlled clinical trial with a 2-by-2 factorial design. It evaluated whether valsartan or nateglinide, in addition to lifestyle modification, could reduce the risk of diabetes and cardiovascular events in people with impaired glucose tolerance who either had CVD or risk factors for CVD.[@R14] Details of the trial, including the protocol, results, and design, have been published.[@R12] A total of 9306 participants from 40 countries participated in the trial for a median of 5.0 years for the diabetes outcome.

Lifestyle modification intervention and identification of incident diabetes {#s1-2}
---------------------------------------------------------------------------

All participants participated in the lifestyle program designed to achieve and maintain a 5% weight loss; reduce dietary saturated and total fats; and increase physical activity to 150 min/week. Study staff provided information at each visit in the first year consisting of written materials and videos with reinforcement via telephone contacts. The co-primary outcome of incident diabetes was defined as the development of a fasting plasma glucose ≥7.0 mmol/L and/or 2-hour glucose (measured 2 hours after oral glucose load) ≥200 mg/dL (≥11.1 mmol/L), confirmed on oral glucose tolerance test performed within 12 weeks. Diagnoses of diabetes made outside of the study were adjudicated by an independent committee blinded to treatment allocation.

Physical activity measures {#s1-3}
--------------------------

Habitual ambulatory activity was assessed objectively using research-grade pedometers (Accusplit AE120, San Jose, California, USA) in all NAVIGATOR Study centers. The pedometers measured purposeful steps taken through a horizontal, spring-suspended lever arm moving vertically with each step, activating an electric circuit, and registering a step. Two weeks after the initial baseline, clinical measurements were taken, participants were fitted with a pedometer and instructed to wear it during waking hours for seven consecutive days. Participants were given a log book and instructed to write down their daily step counts at the end of each day and then return the log book to the study team.

Statistical analysis {#s1-4}
--------------------

Continuous variables are reported as medians (25th, 75th percentiles); categorical variables are reported by proportions. Patient characteristics were compared using the Pearson\'s χ^2^ test or Fisher\'s exact test for categorical variables and with the Kruskal-Wallis test for continuous variables. Unadjusted and adjusted Cox proportional hazards regression models were used to assess the associations of physical activity (pedometer steps) with the clinical outcomes. Covariate adjustment was implemented in three stages. First, we report an unadjusted model. Second, we adjusted for age, sex, and region, avoiding other patient characteristics that might be on the causal pathway between exercise and outcome. Third, a fully adjusted model added all variables significantly contributing to the prediction of diabetes in a baseline model in the original study.[@R16] These factors or variables are listed in the footnotes of the respective tables.

Using a backward selection technique, the adjustment model was a priori selected as only those factors which at baseline were associated with the incidence of type 2 diabetes in this study.

We tested the proportional hazards assumption and linearity assumption for pedometer steps. As the linearity assumption was not satisfied we tested two spline pieces in our models. Since the second piece was distant from being significant, the pedometer data were truncated at 10 000 steps per day. In order to preserve important information on non-missing covariates and improve our multivariable models, pedometer data for the 23% of missing baseline data were handled by multiple imputation. The final models used five imputed data sets, and the results were combined using valid statistical methods that account for imputation variation. In order to investigate whether imputation affected the strength of results, the analysis was repeated for the subset of 7118 participants with complete data. For all outcomes, two parallel analyses were performed: (1) All patients with pedometer measurements (n=7118). (2) Five imputed data sets. The point estimates of the HRs were very similar for these analyses. Since the results from the complete case and imputed (n=9308) data sets were similar, we report here only the results from the imputed data. Note, the linearity assumption was not satisfied for pedometer steps; two spline pieces were tested in the model and the final model only included the first piece, which is equivalent to truncating the pedometer steps at 10 000 steps per day.

A two-sided P value\<0.05 was considered statistically significant for main effects. A P value \<0.1 was considered statistically significant for interactions. Statistical analyses were done using SAS V.9.2 (SAS Institute, Cary, North Carolina, USA).

Results {#s2}
=======

Baseline pedometer data were obtained on 7118 of the 9306 NAVIGATOR participants. Mean (SD) daily steps by quarters at baseline were 1831 (1151), 4652 (659), 7096 (800), and 11 240 (2344) steps per day. [table 1](#T1){ref-type="table"} reports biochemical, anthropometric, and behavioral variables of study participants by quartile of baseline pedometer steps, particularly those included in the adjustment models as indicated by notations and in the footnotes.

###### 

Baseline characteristics by quartiles of pedometer steps

  Characteristic                                                     Quarter 1 (N=2326)    Quarter 2 (N=2327)     Quarter 3 (N=2327)     Quarter 4 (N=2326)      P values
  ------------------------------------------------------------------ --------------------- ---------------------- ---------------------- ----------------------- ----------
  Average daily pedometer steps at month 0.5, median (25th, 75th)    2006 (859, 2859)      4659 (4085, 5216)      7093 (6382, 7754)      10 5699 (9447, 12299)   \<0.0001
  Age at screening, median (25th, 75th), years\*,†                   65 (59, 71)           64 (59, 69)            63 (58, 68)            62 (57, 66)             \<0.0001
  Female, no. (%)\*,†                                                1259 (54.1)           1224 (52.6)            1197 (51.4)            1031 (44.3)             \<0.0001
  Pooled race group: original, no. (%)\*,†                                                                                                                       \<0.0001
   White                                                             1996 (85.8)           1985 (85.3)            1943 (83.5)            1810 (77.8)             
   Black                                                             87 (3.7)              58 (2.5)               55 (2.4)               36 (1.5)                
   Asian                                                             76 (3.3)              116 (5.0)              145 (6.2)              276 (11.9)              
   Other                                                             167 (7.2)             168 (7.2)              184 (7.9)              204 (8.8)               
  Current smoker, no. (%)\*                                          319 (13.7)            246 (10.6)             237 (10.2)             223 (9.6)               \<0.0001
  Region, no. (%)\*,†                                                                                                                                            \<0.0001
   Asia                                                              58 (2.5)              96 (4.1)               134 (5.8)              264 (11.3)              
   Europe                                                            1149 (49.4)           1253 (53.8)            1279 (55.0)            1228 (52.8)             
   Latin America                                                     311 (13.4)            332 (14.3)             362 (15.6)             401 (17.2)              
   North America                                                     716 (30.8)            575 (24.7)             483 (20.8)             372 (16.0)              
   Other                                                             92 (4.0)              71 (3.1)               69 (3.0)               61 (2.6)                
  BMI, median (25th, 75th), kg/m^2^†                                 31.2 (27.7, 35.4)     30.2 (27.1, 33.9)      29.3 (26.7, 32.7)      28.4 (26.0, 31.6)       \<0.0001
  Height, median (25th, 75th), cm                                    165 (158, 173)        165 (158, 172)         165 (158, 172)         165 (159, 172)          0.3250
  Weight, median (25th, 75th), kg                                    85.7 (74.3, 99.0)     83.0 (72.5, 94.5)      80.9 (71.0, 91.3)      79.0 (69.1, 89.1)       \<0.0001
  Waist circumference, median (25th, 75th), cm\*                     104 (96, 113)         101 (93, 110)          99 (91, 107)           98 (89, 105)            \<0.0001
  Systolic BP, median (25th, 75th), mm Hg†                           140 (129, 151)        140 (129, 150)         139 (127, 150)         139 (128, 150)          0.0002
  Diastolic BP, median (25th, 75th), mm Hg                           82 (76, 90)           82 (76, 90)            81 (76, 90)            82 (76, 90)             0.5490
  Pulse rate, median (25th, 75th), bpm\*                             70.0 (64.0, 78.0)     70.0 (62.0, 78.0)      70.0 (63.0, 76.0)      70.0 (62.0, 76.0)       0.0142
  Family history of diabetes, no. (%)                                868 (37.3)            896 (38.5)             882 (37.9)             901 (38.7)              0.7525
  Cardiovascular disease, no. (%)                                    807 (34.7)            743 (31.9)             706 (30.3)             677 (29.1)              0.0003
  Atrial fibrillation/flutter, no. (%)\*                             112 (4.8)             99 (4.3)               79 (3.4)               66 (2.8)                0.0021
  Pulmonary embolism/deep vein no. (%)\*                             42 (1.8)              34 (1.5)               33 (1.4)               20 (0.9)                0.0499
  COPD/emphysema/chronic bronchitis, no. (%)\*                       149 (6.4)             118 (5.1)              104 (4.5)              80 (3.4)                \<0.0001
  Hypertension, no. (%)                                              1812 (77.9)           1827 (78.5)            1763 (75.8)            1814 (78.0)             0.1151
  Congestive heart failure, no. (%)\*                                112 (4.8)             80 (3.4)               81 (3.5)               58 (2.5)                0.0003
  Left ventricular hypertrophy, no. (%)                              72 (3.1)              62 (2.7)               64 (2.8)               70 (3.0)                0.7886
  Cerebrovascular disease no. (%)                                    220 (9.5)             186 (8.0)              181 (7.8)              149 (6.4)               0.0019
  Coronary heart disease, no. (%)\*,†                                716 (30.8)            669 (28.7)             635 (27.3)             606 (26.1)              0.0026
  PAD composite, no. (%)\*                                           99 (4.3)              90 (3.9)               69 (3.0)               51 (2.2)                0.0003
  ECG interpretation, no. (%)\*                                                                                                                                  0.0004
   Normal                                                            1053 (45.3)           1095 (47.1)            1178 (50.6)            1199 (51.5)             
   Clinically insignificant abnormality                              884 (38.0)            865 (37.2)             793 (34.1)             784 (33.7)              
   Clinically significant abnormality                                389 (16.7)            367 (15.8)             356 (15.3)             343 (14.7)              
  Family history of premature CHD, no. (%)                           386 (16.6)            395 (17.0)             411 (17.7)             352 (15.1)              0.1245
  Fasting glucose, median (25th, 75th), mmol/L†                      6.1 (5.7, 6.4)        6.1 (5.7, 6.4)         6.1 (5.7, 6.4)         6.1 (5.7, 6.5)          0.1925
  2-hour glucose, median (25th, 75th), mmol/L†                       9.1 (8.4, 9.9)        9.1 (8.4, 9.9)         9.0 (8.3, 9.9)         9.0 (8.3, 9.9)          0.0665
  HbA1c, median (25th, 75th), %†                                     5.9 (5.6, 6.2)        5.8 (5.6, 6.1)         5.8 (5.5, 6.1)         5.8 (5.5, 6.0)          \<0.0001
  Hemoglobin, median (25th, 75th), g/L\*,†                           146 (137, 155)        147 (138, 155)         146 (138, 155)         148 (139, 156)          0.0052
  LDL cholesterol, median (25th, 75th), mmol/L\*,†                   3.18 (2.53, 3.80)     3.21 (2.60, 3.92)      3.26 (2.62, 3.95)      3.23 (2.63, 3.93)       0.0012
  HDL cholesterol, median (25th, 75th), mmol/L†                      1.22 (1.03, 1.46)     1.24 (1.04, 1.47)      1.24 (1.03, 1.50)      1.25 (1.04, 1.48)       0.0227
  Non-HDL cholesterol, median (25th, 75th), mmol/L                   4.04 (3.35, 4.75)     4.06 (3.41, 4.86)      4.11 (3.46, 4.83)      4.04 (3.36, 4.83)       0.0152
  Non-HDL cholesterol/total cholesterol ratio, median (25th, 75th)   0.77 (0.72, 0.81)     0.77 (0.72, 0.81)      0.77 (0.72, 0.81)      0.76 (0.71, 0.81)       0.1095
  Total cholesterol, median (25th, 75th), mmol/L                     5.30 (4.62, 6.00)     5.39 (4.68, 6.14)      5.40 (4.73, 6.16)      5.35 (4.66, 6.12)       0.0048
  Triglycerides, median (25th, 75th), mmol/L                         1.8 (1.3, 2.4)        1.7 (1.3, 2.4)         1.7 (1.2, 2.4)         1.6 (1.2, 2.2)          \<0.0001
  eGFR, median (25th, 75th), mL/min/1.73 m^2^                        77.7 (65.4, 88.3)     77.8 (67.2, 89.1)      80.1 (69.5, 92.0)      82.6 (71.3, 94.3)       \<0.0001
  Albumin/creatinine ratio, median (25th, 75th), mg/mmol             0.90 (0.55, 2.00)     0.84 (0.51, 1.80)      0.79 (0.50, 1.56)      0.77 (0.50, 1.67)       0.0028
  Log of albumin/creatinine ratio, median (25th, 75th), mg/mmol\*    −0.11 (-0.60, 0.69)   −0.17 (-0.67, 0.59)    −0.24 (-0.69, 0.44)    −0.26 (-0.69, 0.51)     \<0.0001
  Sodium, median (25th, 75th), mmol/L\*                              142 (141, 144)        142.0 (141.0, 144.0)   142.0 (141.0, 144.0)   142.0 (141.0, 144.0)    0.1052
  Potassium, median (25th, 75th), mmol/L                             4.3 (4.1, 4.6)        4.3 (4.1, 4.6)         4.3 (4.1, 4.6)         4.3 (4.1, 4.6)          0.3125
  White blood cell, median (25th, 75th), 10^9^/L                     6.9 (5.8, 8.1)        6.8 (5.8, 8.0)         6.6 (5.7, 7.7)         6.5 (5.5, 7.6)          \<0.0001
  Platelet, median (25th, 75th), 10^9^/L†                            254 (215, 299)        254 (213, 297)         252 (212, 297)         247 (207, 289)          \<0.0001
  Renal dysfunction, no. (%)                                         44 (1.9)              20 (0.9)               16 (0.7)               10 (0.4)                \<0.0001
  α blocker, no. (%)                                                 153 (6.6)             153 (6.6)              135 (5.8)              136 (5.8)               0.5188
  ACE inhibitor, no. (%)                                             197 (8.5)             178 (7.6)              157 (6.7)              144 (6.2)               0.0152
  Antihypertensives, no. (%)                                         1778 (76.4)           1720 (73.9)            1664 (71.5)            1654 (71.1)             \<0.0001
  ARB, no. (%)                                                       11 (0.5)              10 (0.4)               6 (0.3)                3 (0.1)                 0.1396
  Aspirin, no. (%)                                                   892 (38.3)            892 (38.3)             833 (35.8)             808 (34.7)              0.0185
  β blocker, no. (%)                                                 975 (41.9)            923 (39.7)             911 (39.1)             857 (36.8)              0.0054
  Calcium channel blocker, no. (%)                                   784 (33.7)            765 (32.9)             694 (29.8)             769 (33.1)              0.0226
  Diuretic, no. (%)                                                  840 (36.1)            769 (33.0)             714 (30.7)             637 (27.4)              \<0.0001
  Lipid lowering agent, no. (%)                                      907 (39.0)            923 (39.7)             896 (38.5)             851 (36.6)              0.1606

\* In death, myocardial infarction, or stroke model.

† In diabetes mellitus baseline model.

ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; bpm, beats per minute; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PAD, peripheral arterial disease.

[Table 2](#T2){ref-type="table"} reports the HRs, CIs, and P values for the development of diabetes according to the three models, with [figure 1](#F1){ref-type="fig"} showing the unadjusted Kaplan-Meier plot. During the study period, 35.0% (3254 of 9306) of participants developed diabetes. On average, each 2000 greater number of daily steps, up to 10 000, was associated with a 5.5% lower risk of progression to diabetes (HR 0.95, 95% CI 0.92 to 0.97; P\<0.0001) in the unadjusted analysis. The observations remained similar and statistically significant when analyzed adjusting for age, sex, and region of origin (HR 0.95, 95% CI 0.92 to 0.96; P\<0.0001), or when analyzed in the fully adjusted model (HR 0.96, 95% CI 0.94 to 0.99; P=0.0042).

![Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Probabilities of diabetes mellitus (DM) curves were compared using log-rank test (P\<0.0001). Individuals at risk at each visit of follow-up were: 9306 (V0), 8230 (V1), 7524 (V2), 7178 (V3), 6582 (V4), 6229 (V5), 5572 (V6), 4876 (V7), 4275 (V8), 2931 (V9), and 510 (V10).](bmjdrc-2018-000523f01){#F1}

###### 

Clinical outcomes by every 2000 pedometer steps per day (up to 10 000). Development of diabetes (Using five imputed data sets: N=9306, events=3254; C-index=0.527)

  Models               Label                                                         HR     95% CI         χ^2^    P values
  -------------------- ------------------------------------------------------------- ------ -------------- ------- ----------
  Unadjusted model     Average daily pedometer steps per 2000 greater up to 10 000   0.95   0.92 to 0.97   21.74   \<0.0001
  Adjusted model 1\*   Average daily pedometer steps per 2000 greater up to 10 000   0.95   0.92 to 0.96   24.99   \<0.0001
  Adjusted model 2†    Average daily pedometer steps per 2000 greater up to 10 000   0.96   0.94 to 0.99   8.529   0.0042

\*Adjusted for age, sex, and region.

†Adjusted for age; sex; region; race; body mass index; systolic blood pressure; family history of diabetes; composite of history of myocardial infarction (MI), unstable angina, or coronary revascularization; fasting glucose; 2-hour glucose on oral glucose tolerance test; hemoglobin A1C; low-density lipoprotein cholesterol; high-density lipoprotein cholesterol; platelet count; and hemoglobin concentration.

To address the potential for effect modification by gender, we tested for an interaction of gender and pedometer steps on outcome for this manuscript and, the P value was not statistically significant (data not shown).

Discussion {#s3}
==========

In this post hoc observational analysis of NAVIGATOR data, a 24% lower risk of diabetes was seen in those with impaired glucose tolerance and either CVD or cardiovascular risk factors who had a baseline physical activity level of 10 000 steps/day compared with 2000 steps/day. In this cohort, change in ambulatory activity is associated with a reduced risk of cardiovascular outcomes.[@R13] The findings from this study suggest that a reduced risk of type 2 diabetes may have been one mechanism contributing to this previously observed association.

The data linking regular physical activity with diabetes outcomes derive largely from large population-based cohort studies and were reviewed and summarized in the Surgeon General's Report on Physical Activity and Health[@R1] and more recently in the Physical Activity Guidelines Advisory Committee Report[@R2] serving as the basis of the 2008 Physical Activity Guidelines for Americans. In the past, most of these data were derived from self-report or survey tools that, while carefully derived and validated, suffered from a number of inherent confounders and limitations associated with such approaches. Recently, the physical activity epidemiology field has begun to rely on objective measures of physical activity, derived from pedometers or accelerometers, to investigate the associations between regular physical activity and cardiometabolic health.[@R17] A meta-analysis of 17 studies of physical activity in individuals with diabetes shows that each 1 metabolic equivalent hour/day of greater physical activity (roughly equivalent to 20 min of walking or 2000 steps) incrementally was associated with a 9.5% (5.0%**--**13.8%)%) and 7.9% (4.3%**--**11.4%)%) lower risk of all-cause mortality and CVD risk.[@R18] The data in this report from the NAVIGATOR Study support and confirm these associations for CVD outcomes in the novel setting of a rigorously conducted and assessed prospective clinical pharmaceutical trial in a large international population broadly representative of those targeted with diabetes and CVD prevention programs in routine clinical care. In the setting of an enriched clinical trial, individuals carry a greater absolute risk for events (in this case diabetes) than would be available in a generalized population-based setting. In addition, the clinical trial setting carries the advantage of regular, close follow-up; standardized collection and adjudication of events; in this case and, most important, repeat and regular follow-up of clinical laboratory testing (eg, oral glucose tolerance testing) to diagnose diabetes mellitus.

The results of the analysis presented here support the independent effects of objectively measured physical activity on metabolic outcomes and the notion that all pharmaceutical studies of incident or established diabetes should consider the independent influence of physical activity levels on the trial outcomes, as is done for other relevant covariates. As physical activity was measured by self-report in the major prevention trials, it has not been possible to use these studies to precisely define the importance of physical activity in the prevention of type 2 diabetes. This study aims to assess the association between physical activity and diabetes progression using an objective measurement tool (a pedometer) with a universally understood metric (steps/day) in the context of an international cohort.

This study has several strengths. Physical activity was objectively measured using a readily available simple instrument---the pedometer. The collection of a plethora of clinical data on the study subjects, the uniformity of the study population, and the prospective nature of the data collection provide the opportunity to control for a broad range of clinical characteristics strengthening confidence in the strength of the observed associations.

There are several limitations. The study was not designed to test the association between physical activity and diabetes outcomes, opening the possibility for unmeasured confounding. That is, subjects were not randomized on the basis of baseline physical activity; nor were they randomized to changes in physical activity. Further, less active individuals tend to be the least healthy ---this is true of any population. We have attempted to account for this by adjustment for a comprehensive list of factors found to be associated with the incidence of type 2 diabetes in the fully adjusted model. However, we acknowledge that confounding by unmeasured confounders---or residual confounding from measured factors---remain possibilities. Still, the dose-response relation between habitual physical activity level and the clinical outcomes provides confidence regarding the fidelity of the observations. Further, since the hypothesis being tested was not a primary study objective, there were missing data on objective measures of physical activity; however, we believe that this limitation was effectively addressed with the imputation and sensitivity analyses. Also, due to the nature of the study tool, we could not address whether intensity of physical activity was related to outcome. That would require accelerometry or another similar tool to address this important question in this setting.

It also is important to make the distinction between physical activity and cardiorespiratory fitness; this study assessed the former, not the latter. There is a strong association between cardiorespiratory fitness and cardiometabolic outcomes as well as all-cause mortality.[@R19] Further, there is an association between habitual physical activity and cardiorespiratory fitness; however, as genetics play a strong role in the determination of this relation and in cardiorespiratory fitness itself, the relation is far from perfect. The study reported here only applies to the relation of baseline habitual physical activity and incident diabetes mellitus. There was no measure of fitness in this study.

The LOOK AHEAD investigators did not observe a significant effect of a combined lifestyle intervention including physical activity on cardiovascular outcomes in older individuals with type 2 diabetes mellitus.[@R11] Several differences in the design of that study and the one reported herein may explain the different observations. Probably the most important difference is in the study populations. LOOK AHEAD studied those with established diabetes, often established for some lengthy period, and NAVIGATOR was designed to study events in those at high risk of developing diabetes, but without frank disease at onset. It may be that the state of the vasculature in those with established disease is not amenable to modification by lifestyle interventions, including physical activity. This distinction would be worth testing in a prospective study. That being said, as they are supported by observations in a recent publication from our group showing that even modest changes in physical activity during the study are reflected in better cardiovascular outcomes, we are confident in the observations reported here.[@R13]

Conclusions {#s4}
===========

In this secondary analysis of a clinical trial where participants were already at high risk of cardiovascular events and progression to diabetes, each greater 2000-step per day difference in baseline activity (roughly equivalent to 20 min of moderate-paced walking per day) was associated with a 5.5% lower risk of developing diabetes over the course of the study, even when studied in a fully adjusted model containing other pertinent clinical elements. This observation demonstrates the utility of objective measures of physical activity in clinical trials and suggests that assessments of lifestyle in pharmacologic outcomes trials should be part of regular clinical trials and clinical practice in general.
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